Inogen, Inc.·Healthcare

INGN broadens beyond portable oxygen concentrators into home respiratory care, but U.S. revenues face pressure from channel shifts.

Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript

Inogen posts higher Q1 revenues and improved gross margin as international portable oxygen demand offsets weaker U.S. sales.

Inogen (INGN) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.25 per share a year ago.

BEVERLY, Mass.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces First Quarter 2026 Financial Results.

Inogen, Inc (NASDAQ: INGN - Get Free Report) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $6.29 and traded as high as $7.38. Inogen shares last traded at $6.99, with a volume of 201,150 shares traded. Analyst Ratings Changes Separately, Freedom Capital
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Healthcare
Medical - Devices
766
2014-02-14
1.65